Corporate ActionMay 29, 2026, 05:01 PM
Skye Bioscience Increases Authorized Shares to 300M
AI Summary
Skye Bioscience, Inc. increased its authorized common stock from 100 million to 300 million shares following stockholder approval at its 2026 Annual Meeting. The amendment to the Articles of Incorporation was filed on May 28, 2026, allowing for future share issuance without affecting current outstanding shares. Additionally, stockholders re-elected six directors, ratified CBIZ CPAs P.C. as the independent auditor for 2026, and approved executive compensation on an advisory basis.
Key Highlights
- Skye Bioscience increased authorized common stock from 100,000,000 to 300,000,000 shares.
- Stockholders approved the Charter Amendment with 20,594,286 votes for.
- Six directors were re-elected to the Board for a one-year term.
- CBIZ CPAs P.C. was ratified as the independent auditor for 2026 with 22,802,045 votes for.
- Executive compensation was approved on an advisory basis with 12,696,055 votes for.
- A quorum was present at the Annual Meeting with 23,529,424 shares (66.98%) represented.
Price Impact
More from SKYE